Abstract
Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases.
The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
Keywords: Crohn's disease, inflammatory bowel disease, interleukin-13, lebrikizumab, pleiotropic, tralokinumab, ulcerative colitis.
Current Drug Targets
Title:Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Volume: 14 Issue: 12
Author(s): Manol Jovani, Gionata Fiorino and Silvio Danese
Affiliation:
Keywords: Crohn's disease, inflammatory bowel disease, interleukin-13, lebrikizumab, pleiotropic, tralokinumab, ulcerative colitis.
Abstract: Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases.
The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
Export Options
About this article
Cite this article as:
Jovani Manol, Fiorino Gionata and Danese Silvio, Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990170
DOI https://dx.doi.org/10.2174/13894501113149990170 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Potential Assessment of 2-Substituted Quinazolin-4(3<i>H</i>)-ones as Inhibitors of Phosphodiesterase-I and Carbonic Anhydrase-II
Medicinal Chemistry Concomitant Gene Mutations of MBL and CYBB in Chronic Granulomatous Disease: Implications for Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Local Renin-Angiotensin II Systems, Angiotensin-Converting Enzyme and its Homologue ACE2: Their Potential Role in the Pathogenesis of Chronic Obstructive Pulmonary Diseases, Pulmonary Hypertension and Acute Respiratory Distress Syndrome
Current Medicinal Chemistry Expectancy and the Treatment of Depression: A Review of Experimental Methodology and Effects on Patient Outcome
Current Psychiatry Reviews Immunomodulatory and Anti-Inflammatory Activities of Statins
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Neutrophil Apoptosis and Removal of Apoptotic Cells
Current Drug Targets - Inflammation & Allergy Decoding the Inter-Relationship between Sleep Disorders and Alzheimer’s Disease Pathogenesis
CNS & Neurological Disorders - Drug Targets Cellular Players in Lung Fibrosis
Current Pharmaceutical Design Synthesis of Novel Benzoquinones with Anti-Inflammatory Activity
Letters in Drug Design & Discovery Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Mast Cells in Lung Homeostasis: Beyond Type I Hypersensitivity
Current Respiratory Medicine Reviews New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Time-Effect of Formoterol Added to Inhaled Fluticasone on Exercise- Induced Bronchoconstriction in Asthmatic Adolescents
Current Respiratory Medicine Reviews Therapeutic Monoclonal Antibodies: Strategies and Challenges for Biosimilars Development
Current Medicinal Chemistry Effect of Antenatal Steroids on Haemodynamics in the Normally Grown and Growth Restricted Fetus
Current Pediatric Reviews Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Hot Topic: TRP Channels as Therapeutic Targets)
Current Topics in Medicinal Chemistry